Introduction
More than 20 years of research have provided detailed insight into the multifaceted and oftentimes pivotal roles of the interplay between the chemokine receptor 4 (CXCR4) and its endogenous ligand CXCL12, both in physiology and in a variety of pathological conditions [1, 2] . The central functional element in these processes is the migration of CXCR4-expressing cells towards tissues with high
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International Publisher local CXCL12 expression and their retention, homing and differentiation at these sites. Physiologically, this includes the recruitment of stem and progenitor cells during embryogenesis, hematopoiesis and neoangiogenesis as well as leukocyte trafficking during immune response [2] . In cancer, chemotactic CXCR4/CXCL12 interactions fulfil a variety of tumor-growth supporting functions, including direct autocrine stimulation of proliferation and angiogenesis, promotion of tumor invasiveness as well as metastasis of CXCR4-expressing tumor cells to mesenchymal stromal tissues with high CXCL12 expression (liver, bone marrow, lung, lymph nodes) [3] [4] [5] . An increasing number of preclinical studies underline the relevance of the multiple CXCR4/CXCL12 mediated interactions between cancer cells and the tumor microenvironment (fibroblasts, endothelial cells, immune cells), which provides a protective and supportive niche for tumor growth [6] .
CXCR4 overexpression is documented for more than twenty human tumor types, ranging from hematological malignancies to solid tumors [7] . Furthermore, high CXCR4 expression has been found to be significantly associated with distant metastasis and with poor overall and disease-free survival in patients with e.g. breast, prostate, pancreatic and lung cancer, lymphoma and leukemia and thus represents an important independent prognostic factor in these diseases [8] . The accurate in vivo assessment of the level and kinetics of CXCR4 expression in a given tumor entity may therefore not only provide relevant information on tumor biology and tumor grade as well as on its metastatic potential, but may also allow selection of patients eligible for CXCR4-targeted therapies.
Intense efforts have therefore been directed towards the development of a suitable CXCR4-targeted molecular imaging agent in recent years [9, 10] . The only compound that has entered clinical application so far is the small cyclic pentapeptide [ 68 Ga] pentixafor [11] . With its high affinity and selectivity for human CXCR4, rapid renal excretion and very low non-specific background accumulation, it allows sensitive and high-contrast imaging of CXCR4-expressing tissues in vivo using positron emission tomography (PET). Besides its successful application in patients with lymphoma [12] , multiple myeloma [13] , AML [14] , SCLC [15] , glioblastoma [16] or other solid tumors [17] such as non-small cell lung cancer [18] or adrenocortical cancer [19] , [ 68 Ga] pentixafor-PET has recently been shown to be a valuable tool for the in vivo detection of inflammatory processes e.g. after myocardial infarction [20] [21] [22] or ischemic stroke [23] as well as in atherosclerosis [24] or urinary tract infection [25] . The possibility to non-invasively quantify CXCR4 expression using [ 68 Ga ]pentixafor-PET is anticipated to further strengthen the emerging role of CXCR4 as a diagnostic marker, matching its already established importance as a therapeutic target.
Currently, several potent CXCR4 antagonists are being investigated in clinical trials for CXCR4-directed anticancer therapy [4, 26, 27] . Their therapeutic effect, both in hematological and solid cancers, has been shown to be primarily based on an effective prevention of distant organ metastasis [28] . Furthermore, by mobilizing tumor cells from their chemoprotective microenvironment into the peripheral blood, CXCR4 antagonists also act as potent chemo/radiosensitizers [4] . Combining CXCR4 inhibition with chemo-or radiotherapy has therefore been shown to provide a significant therapeutic advantage relative to the respective conventional monotherapy alone in preclinical mouse models [29] [30] [31] . In contrast, CXCR4 targeting alone, although effective in preventing metastasis, only has negligible effect on primary tumor growth. In this context, CXCR4-targeted PRRT might represent a highly promising alternative treatment concept in cancer therapy [32] .
By the direct administration of therapeutic radionuclides conjugated to a CXCR4 targeting vector, high doses of ionizing radiation may be specifically deposited in CXCR4-overexpressing tissues with high precision, with significantly reduced systemic side effects for the patient. Since PRRT requires very low mass amounts of the CXCR4-targeted probe, unwanted pharmacological side effects are highly improbable to occur. As opposed to "conventional" CXCR4-directed therapeutic approaches, the efficacy of PRRT also relies on the so-called "crossfire effect" and is thus not restricted to cells expressing the target epitope. In contrast, even in the case of pronounced intratumoral heterogeneity in CXCR4 expression [12] or insufficient vascularization, the choice of a radionuclide with an adequate particle range in tissue allows delivery of therapeutic radiation doses to areas of the tumor with low or no target expression or limited target accessibility.
To exploit the potential of such an approach, the current study was directed towards implementing a CXCR4-targeted theranostic concept based on the pentixafor scaffold as a targeting vector.
The concept of using a peptide-receptor-targeted "theranostic agent" for radiolabeling with both diagnostic (PET/SPECT) and therapeutic radionuclides has been pioneered by the introduction of radiolabeled somatostatin analogs, e.g. Ga/ 177 Lu]PSMA-617 [35] for theranostics of metastatic castration resistant prostate cancer. It is important to note, that these approaches invariably use one single precursor molecule for both diagnostic and therapeutic applications. This has certain practical advantages, but does not fully account for the fundamentally different pharmacokinetic requirements which need to be met by a diagnostic agent and the corresponding therapeutic analog. Sensitive high-contrast diagnostic imaging relies on the fast and high accumulation of the respective tracer in the target tissue as well as rapid background clearance, usually within ≤2h p.i.. In contrast, therapeutic targeting in PRRT primarily aims at achieving maximal activity uptake and retention in the tumor lesions, all the while keeping radiation doses to non-target and excretion organs to a minimum. Thus, longer circulation times and delayed whole-body clearance, which in the case of small bioactive peptides are primarily the result of efficient plasma protein binding as a consequence of a suitably balanced lipophilicity, are desirable features for PRRT applications, leading to prolonged availability of the therapeutic agent for target binding.
These considerations as well as our previous finding, that the highly optimized structure of Ga-pentixafor does not tolerate an exchange of Ga 3+ by other M 3+ ions (e.g. Lu or Y) without a significant loss in CXCR4 affinity [36, 37] , led towards the development of pentixather (3-iodo-D-Tyr 1 -pentixafor, Figure 1 ) as a dedicated probe for CXCR4-targeted PRRT and as the companion therapeutic to [ 68 Ga Figure 1 ) was prepared via solid phase peptide synthesis [37] and consecutive solution phase functionalization with 4-aminomethyl benzoic acid (AMBS) and DOTA [40] , followed by direct iodination of Tyr 1 in the unprotected peptide using N-iodosuccinimide [41] . Analytical data on pentixather and its nat Lu-, nat Y-and nat Bi-complexes are provided in the supplementary data.
Materials and Methods

Peptide synthesis
Pentixather (cyclo(D-3-iodo-Tyr 1 -[NMe]-D-- Orn 2 (AMBS-DOTA)-Arg 3 -2-Nal 4 -Gly 5 ),
Radiolabeling
For 177 Lu-labeling, pentixather was dissolved in water to yield a 1 mM solution. Of this solution, the required volume was added to 177 LuCl3 in 0.04 M HCl (ITG/ITM, Garching, Germany; activity concentration: 370 MBq/500 µl) to achieve a peptide-to- 177 Lu-activity ratio of 1 nmol peptide per 225 MBq 177 LuCl3. To this mixture, 1 M NH4OAc was added (calculated to be 10% of total reaction volume), and the mixture was heated to 95°C for 20 min. After cooling and determination of the radiochemical purity (usually >98%), the reaction mixture was diluted with PBS to the desired activity concentration and used as such for in vitro and in vivo studies.
For patient application, [ 177 Lu]pentixather was prepared using a Scintomics GRP synthesis module (Scintomics, Fürstenfeldbruck, Germany). Briefly, a solution of 150 µg pentixather and 7 mg gentisic acid in 600 µl sodium acetate buffer (pH = 4-5) was added to a solution of 300 MBq [ 177 Lu]Cl3 in 0.04 M hydrochloric acid (ITG/ITM) and heated for 35 minutes at 95°C. The product was diluted with saline and passed through a sterile filter (0.22 µm) into a sterile vial.
Radiochemical purity was determined using radio-TLC and analytical radio-HPLC. Radio-TLC was carried out using Agilent iTLC silica gel impregnated chromatography paper (Agilent, Waldbronn, Germany) and two different mobile phases, i.e. A) 0.1 M aq. sodium citrate and B) a 1:1 (v/v) mixture of 1 M aq. NH4OAc and MeOH. TLC-strips were analyzed using a Bioscan TLC analyzer.
Lipophilicity
The lipophilicity of [ 177 Lu]pentixather was determined via a modified shake-flask method as described [42] .
In vitro studies
CXCR4 affinity
Affinities for human CXCR4 (hCXCR4) were determined in competitive binding assays (IC50) [11] using Jurkat lymphoma cells (4x10 5 To allow data normalization, nat Ga-pentixafor and FC-131 were included as references in this study. Experiments were performed in triplicate with n=3 per concentration in each experiment. IC50 values were calculated using GraphPad Prism 6.01 (Graph Pad Software, San Diego, USA).
Receptor selectivity
The receptor selectivity of [ 177 Lu]pentixather was investigated using CHO-K1 cells transiently transfected with h(HA)CXCR4, m(HA)CXCR4, hCXCR7 and mCXCR7 (negative control: untransfected CHO-K1 cells) as described [12] .
Comparative binding studies using various cell lines After incubation, the tubes were centrifuged (3 min, 1300 rcf, Megafuge 1.0, Heraeus Thermo Scientific) and the supernatant was carefully removed. After washing twice with 200 µL of cold HBSS, the amount of bound radioligand in the cell pellet was quantified using a γ-counter.
Binding and internalization kinetics
Daudi cells (2 × 10 5 cells/sample) in assay medium were incubated with [ 177 Lu]pentixafor (1 nM) at 37 °C for different time points up to 60 min in the presence (non-specific binding) or absence (control) of 100 µM AMD3100 (n=3 per concentration). Samples were then centrifuged, the supernatant (free radioligand) was removed and combined with 250 µL HBSS used for washing the cells. To differentiate between receptor bound (acid releasable) and internalized radioactivity, cells were then washed twice with 250 µL ice cold acid wash buffer (0.02 M NaOAc buffered with AcOH to pH = 5). The amount of free, acid releasable and internalized radioligand in the cell pellet, respectively, was quantified using a γ-counter.
Binding to human blood cells and plasma protein binding
To 225 µL samples of heparinized whole blood from a healthy donor, 25 µL of PBS (n=3, total binding) or 25 µL of 1 mM AMD3100 in PBS (n=3, non-specific binding) were added, immediately followed by the addition of [ 177 Lu]pentixather in PBS (20 µL). After 15 min at RT, erythrocytes were spun down at 700·g for 5 min, and washed twice with 200 µL PBS. The combined supernatants of each sample were then centrifuged at 6200·g for 5 min, and the pellet (leukocytes and platelets) was washed once with PBS. The amount of activity in the three fractions containing erythrocytes, leukocytes and cell-free plasma, respectively, was quantified using a γ-Counter.
For the determination of plasma protein binding, fresh human plasma (400 µL) was incubated with [ 177 Lu]pentixather for 15 min at RT. Then, a 300 µL sample was transferred into an ultracentrifugation device (Amicon Ultra 0.5 mL, 30K, regenerated cellulose, Merck Millipore, Darmstadt, Germany). Upon ultrafiltration at 14.000·g for 6 min, the activity in 100 µL aliquots of the ultrafiltrate and of unfiltered plasma was quantified using a γ-Counter. Additionally, binding of [ 177 Lu]pentixather to human serum albumin (HSA) was quantified via a previously described gradient HPLC method [43] with minor modifications using a Chiralpak HSA column (50x3 mm, 5µm, Chiral Technologies Europe) equipped with a Chiralpak HSA Guard Cartridge (10x3 mm, 5µm). For elution (flow rate 0.5 mL/min), 50 mM ammonium acetate (pH=6.9, solvent A) and 2-propanol (solvent B) and a linear gradient (0-3 min: 0% B, 3-15 min: 0-20% B) were used.
Flow Cytometry
Membrane expression levels of CXCR4 were determined by flow cytometry (Cyan 9C, Beckman Coulter, Krefeld, Germany) using a PE-conjugated anti-CXCR4 antibody (hCD184; clone 12G5; BD Pharming, Becton Dickinson, Bergisch-Gladbach, Germany) and its isotype control (mouse IgG 2a,κ) according to the manufacturer's instructions. Data were analyzed using FlowJo software.
In vivo animal studies
Tumor model
For the induction of tumor growth, female CB-17 SCID mice (6-8 weeks, Charles River, Sulzfeld, Germany) were injected subcutaneously with app. 5×10 6 Daudi cells suspended in 100 µL of a 1:1 (v/v) mixture of serum free culture medium and Matrigel (BD Biosciences, Heidelberg, Germany). The Daudi xenograft model was chosen due to the well characterized endogenous CXCR4 expression on these cells, which is comparable to that of the non-tumorigenic Jurkat cells used for the in vitro assays [12] . Within 10-21 days, solid palpable tumors had grown (100-800 mg), and the animals were used for the experiments. All animal experiments were performed in accordance with current animal welfare regulations in Germany (approval #55.2-1-54-2532-71-13).
Biodistribution studies
For biodistribution studies, animals (n=4-5 per group) were injected intravenously with ≈1.5-4 MBq (depending on the specific activity of the preparation; the injected peptide amount was kept constant at 0.16 nmol peptide per mouse) of [ 177 Lu]pentixather in PBS (100 µL) into the tail vein under isoflurane anesthesia. CXCR4-specificity of binding was determined via coinjection of 50 µg AMD3100 per mouse. The animals were sacrificed 1, 6, 48, 96h and 7d post injection (p.i.), and the organs of interest were dissected. The radioactivity was measured in weighted tissue samples using a γ-counter. Data are expressed in % ID/g tissue (mean ± SD).
Investigation of in vitro/in vivo stability
To determine the stability of [ 177 Lu]pentixather in human plasma, 1-2 MBq of the tracer were incubated in 500 µL fresh human plasma (37° C, 1 h). Plasma proteins were removed by precipitation with acetonitrile, centrifugation and ultrafiltration using an Amicon Ultra 30K centrifugal filter (Merck Millipore, Darmstadt, Germany). In vivo stability of [ 177 Lu]pentixather was investigated by injection of 30-40 MBq into the tail vein of anesthetized CB-17 SCID mice (n=3). Animals were sacrificed at 1h p.i., and blood and urine were collected. After centrifugation of the blood samples and isolation of cell-free plasma, sample preparation was performed as described above. All samples were analyzed via Radio-TLC and Radio-RP-HPLC using a Chromolith RP-18e performance column (4.6x150 mm) and isocratic elution with 3% acetonitrile (0.1% TFA) in 0.1% TFA for 3 min, followed by a linear gradient of 3-95% acetonitrile (0.1% TFA) in 0.1% TFA within 6 min at a flow rate of 3 mL/min.
Dosimetry and patient imaging
Based on the tissue uptake data obtained from the biodistribution study in mice, an extrapolation of the absorbed doses to humans was performed. This involved the scaling of the time-integrated activity coefficients (TIACs) and the subsequent calculation of the absorbed doses from the animal biodistribution data using two different methods. Mouse TIACs were calculated using the software solution NUKFIT [44] . The dose calculation was performed for a selected group of organs using OLINDA/EXM V1.1 [45] . Details on the extrapolation methodology used are provided in the supplementary data.
Human
Maximum tolerable treatment activity was determined in a pre-therapeutic dose assessment from scintigraphic images consecutively acquired within 4d after intravenous injection of 197 MBq [ 177 Lu]pentixather. Absorbed doses in organs at risk were deduced from the highest activity concentration measured by SPECT/CT in a contiguous 1 ml volume. Based on a dose limit of 23 Gy for the kidneys, the maximum safe activity was estimated to be 9.1 GBq [ 177 Lu]pentixather (if combined with subsequent stem cell transplantation). After treatment with 7.8 GBq [ 177 Lu]pentixather, tracer kinetics were measured by SPECT/CT and serial planar imaging up to 13d p.i.. All scintigraphic images were acquired with a 20% energy window at 208 keV using dual-head gamma-cameras (Siemens Symbia E for planar imaging, Symbia T2 for SPECT/CT) equipped with medium-energy collimators and calibrated by phantom measurements with 177 Lu activity standards. Pharmacokinetic data were fitted by bi-exponential decay functions and normalized to activity concentrations measured quantitatively by SPECT/CT. SPECT/CT data were reconstructed using 3-dimensional ordered-subsets expectation maximization (6 subsets, 6 iterations, 6-mm gaussian filter) with corrections for scatter and attenuation to obtain absolute activity quantification in 4.8 mm voxels (0.11 cm³).
Results
CXCR4 affinity and selectivity
The hCXCR4 affinities of pentixather and its nat Lu-and nat Y-complexes are summarized in Table 1 . Since the experimental setup of the competitive binding assay was modified compared to previous studies [11] , the reference compounds nat Ga-pentixafor and FC-131 were re-assayed under the novel conditions (increased cell number per sample, higher BSA content in assay medium) for comparison and data normalization. Compared to nat Ga-pentixafor, both nat Lu-pentixather and nat Y-pentixather show improved hCXCR4 affinities. As previously observed for pentixafor and its nat Ga-and nat In-analogs, metal chelation leads to an enhanced hCXCR4 affinity of nat Lu-pentixather and nat Y-pentixather compared to non-complexed pentixather (Table 1) . However, this effect is by far less pronounced than in the case of pentixafor/ nat Ga-pentixafor, where Ga-complexation lead to a 30-fold increase in receptor affinity [37] .
[ 177 Lu]pentixather exhibits very high selectivity and specificity for hCXCR4 (Figure 2A ) and only low specific binding to hCXCR7, an alternative receptor for CXCL12, and murine CXCR4 (mCXCR4), while virtually no binding to mCXCR7 is observed. 
Binding and internalization
CXCR4-mediated cellular binding of [ 177 Lu]pentixather was investigated in a variety of human lymphoma (Daudi), multiple myeloma (MM1.S, RPMI, OPM-2) and acute myeloid leukemia cell lines (THP-1, MV4-11, Molm-13) ( Figure 2C ). Tracer uptake in all cell lines closely correlated with the respective CXCR4-expression levels determined via flow cytometry ( Figure 2D) To determine CXCR4 specificity of tracer uptake (6h p.i.), 50 µg AMD3100 (2 mg/kg) were coinjected. Data are given in %iD/g and are means ± SD.
In vivo biodistribution studies and metabolite analysis
The biodistribution of [ 177 Lu]pentixather in Daudi human B-cell lymphoma xenograft bearing CB-17 SCID mice is summarized in Table 2 . Compared to the reference [ 68 Ga ]pentixafor (logP= -2.90) [12] (Figure 3A) , [ 177 Lu]pentixather (logP= -1.76) exhibits slightly increased blood activity levels at 1h p.i., accompanied by enhanced overall background accumulation. Furthermore, the 177 Lu-labeled peptide shows comparably high initial uptake in all excretion organs. However, while activity is rapidly cleared from stomach, intestines and the kidneys, hepatic activity levels remain persistently high up to 7d p.i., suggesting tracer retention in the liver rather than slow and continuous hepatobiliary excretion of the tracer. However, as demonstrated by coinjection of an excess of unlabeled competitor (2mg/kg AMD3100) at 6h p.i., hepatic [ 177 Lu]pentixather uptake is at least partially blockable, which hints towards a certain contribution of CXCR4-mediated liver accumulation.
Since, as opposed to the highly hCXCR4-selective ligand [ 68 Ga]pentixafor, [ 177 Lu]pentixather seems to exhibit some affinity to mCXCR4 (Figure 2A ), CXCR4-specificity of tracer uptake was not only observed in the Daudi xenografts, but also in mouse tissues with endogenous CXCR4 expression, i.e. liver, spleen and the bone marrow (femur). Overall, [ 177 
Dosimetry
TIACs and absorbed dose coefficients for [ 177 Lu]pentixather in humans were extrapolated from mouse biodistribution data using two alternative extrapolation methods. Details on the methodology, a list of the TIACs for organs of relevance for dosimetry, a full list of the corresponding absorbed doses, and information on the absorbed dose by β-particles and photons are supplied in the supplementary data.
The highest TIAC was calculated for the liver (method 1: 20.4 h; method 2: 11.2 h), with values for all other tissues, including the kidneys, being considerably lower. Consequently, the highest extrapolated dose coefficients were found for the liver (0.95 mGy/MBq (method 1) and 0.52 mGy/MBq (method 2), respectively), with estimated values for other organs at risk (kidneys, spleen, red bone marrow) being by a factor of 5-10 lower, depending on the extrapolation method used (Table 3) .
Extrapolated liver absorbed doses (Table 3 ) are in good agreement with the human data obtained in the multiple myeloma patient in this study ( Figure  3B ), i.e. 0.95 mGy/MBq in the pre-therapeutic dose assessment and 0.75 mGy/MBq during [ 177 Lu]pentixather therapy. For the kidneys, however, the absorbed dose observed in the pre-therapeutic dosimetry assessment of the patient (2.51 mGy/MBq) was substantially higher than the values extrapolated from the mouse biodistribution data ( As shown in Figure 3C , uptake of [ 177 Lu]pentixather was higher in tumor lesions than in all other organs, leading to tumor/kidney and tumor/liver dose ratios of 3.1 and 6.4, respectively. Substantial [ 177 Lu]pentixather accumulation was also observed in the spleen and bone marrow of the patient, resulting in organ doses of 0.81 and 0.97 mGy/MBq to spleen and bone marrow, respectively, and thus to myeloablation by [ 177 Lu]pentixather PRRT, which represents a therapy objective in patients with multiple myeloma. Again, extrapolated doses from the mouse biodistribution data (Table 3) have limited predictive value for the human situation, which in this case, however, is the result of the low affinity of [ 177 Lu]pentixather to mCXCR4 and thus an underproportionally low tracer accumulation in mouse spleen and bone marrow as compared to humans. Data were calculated using OLINDA/EXM using two different scaling methods (for details see supplementary data).
Discussion
Given the importance of CXCR4 as an oncological target, the objective of this study was the development of a suitable therapeutic counterpart to the already established PET imaging probe [ 68 Ga] pentixafor [11] [12] [13] [14] [15] [16] [17] and to thereby provide a first and sustainable CXCR4-targeted theranostic concept.
As shown in Figure 1 , the only structural difference between pentixafor and pentixather is the iodine-for-H-substitution in Tyr 1 in the peptide backbone. Given the fact that D-Tyr 1 iodination is a straightforward one-step synthetic procedure [41] , only minimal synthetic effort is required for obtaining the dedicated therapeutic probe, which represents a considerable practical advantage. Despite representing a minimal structural modification compared to pentixafor, however, iodination of D-Tyr 1 conveys several characteristics to pentixather that represent essential prerequisites for successful application in CXCR4-targeted PRRT.
Firstly, introduction of 3-iodo-D-Tyr 1 not only substantially improves CXCR4 affinity of the unlabeled peptide as such, it also confers much greater flexibility towards chelation of different (radio)metal ions by the DOTA moiety. As opposed to pentixafor, where exchange of Ga 3+ for In 3+ or Lu 3+ had led to an app. tenfold decrease in receptor affinity [37] , complexation of Lu 3+ , Y 3+ and Bi 3+ by pentixather even has beneficiary effect on CXCR4 affinity, leading to analogs with two-to fivefold higher CXCR4 affinity than Ga-pentixafor in the same assay ( Table 1) .
The enhanced affinity of the respective pentixather (radio)metal chelates towards hCXCR4 is also evident in the improved in vitro CXCR4 targeting efficiency of [ 177 Lu]pentixather; it not only shows high and specific uptake in CXCR4 expressing human cancer cell lines (Figure 2C ), which accurately reflects CXCR4 expression levels, but also improved CXCR4-mediated tracer accumulation in Daudi lymphoma cells compared to the reference [ 68 Ga] pentixafor.
Interestingly, however, internalization efficiency of [ 177 Lu]pentixather was found to be considerably lower than that of [ 68 Ga] pentixafor. Most probably, slight differences in the agonistic/antagonistic profile of the compounds may be responsible for this observation, and ongoing studies are aimed at elucidating these relationships.
It is important to note, that recent studies on radiolabeled somatostatin receptor (sst) agonists and antagonists have induced a paradigm shift concerning the relevance of efficient ligand internalization for high in vivo tumor accumulation and retention. As opposed to previous assumptions, the in vivo tumor uptake and retention of non-internalizing sst-antagonists, both in preclinical mouse models and in patients with neuroendocrine tumors, is dramatically increased compared to efficiently internalizing agonists [47] . The present data on [ 177 Lu]pentixather also demonstrate the negligible effect of ligand internalization on the in vivo performance of the compound. Despite different internalization efficiencies, [ 177 Lu]pentixather and [ 68 Ga] pentixafor show comparable uptake in the Daudi lymphoma xenografts at 60 and 90 min p.i., respectively ( Figure 3A) . Even more importantly, [ 177 Lu]pentixather shows slow late-phase tumor washout kinetics and persistent activity retention in the tumor xenografts up to 7 d p.i. (Table 2) , which is the primary prerequisite for delivery of sufficient radiation doses to the tumor during PRRT.
Besides its effect on CXCR4 affinity, CXCR4 targeting efficiency and species selectivity, the iodination of Tyr 1 has a pronounced impact on the physicochemical properties of [ 177 Lu]pentixather and consequently its pharmacokinetic behavior. The lipophilicity of [ 177 Lu]pentixather is increased by more than an order of magnitude compared to [ 68 Ga] pentixafor. On the one hand, this leads to enhanced plasma protein binding, which in turn entails a slightly delayed activity clearance from the circulation ( Figure 3A) and from the background tissues. As mentioned, this circumstance is expected to have a beneficiary influence on tracer uptake in the target tissues, since it leads to prolonged tracer delivery to the tumor site, given a sufficient metabolic stability of the targeted agent. In the case of [ 177 Lu]pentixather, no significant tracer degradation or deiodination was observed up to 1h p.i. in mice and in human serum (see supplementary Figure 1 ), indicating sufficient tracer stability for efficiently exploiting the aforementioned effect. In humans, the extended availability of [ 177 Lu ]pentixather for mCXCR4, tracer binding to mouse blood cells was not expected and thus not investigated in detail; in vitro studies using human full blood, however, showed that a total of app. 6% of the added activity were specifically bound to both erythrocytes and leukocytes/platelets, with the latter fraction primarily contributing to the effect ( Figure 2E ). This finding is in accordance with the documented high CXCR4-expression on human leukocytes [48] Figure 3A, 3C, 3D ) supports this assumption. It is important to note, however, that in mice, the hepatic uptake of [ 177 Lu]pentixather is overproportional to what would have been expected on the basis of differences in lipophilicity between structurally closely related peptides as the determining factor alone [42] . Furthermore, both in mice and in humans, virtually none of the initial hepatic activity is cleared into the intestines within the observation period (Table 2 and Figure 3B ), indicating effective trapping of the activity in liver tissue by a yet unknown mechanism.
In mice, at least part of this uptake seems CXCR4 mediated, as demonstrated by the reduction of the hepatic [ 177 Lu]pentixather accumulation by coinjection of a high dose of competitor (2 mg/kg AMD3100; Table 2 ). This observation may be accounted for by the documented expression of functional CXCR4 in the mouse liver [49] in combination with the observed, albeit low affinity of [ 177 Lu]pentixather to mCXCR4 (Table 1 ). In humans, CXCR4 expression in normal liver has also been described [50] . However, since [ 68 Ga] pentixafor, despite comparably high hCXCR4 affinity, shows virtually no hepatic accumulation/retention in patients [12] [13] [14] [15] [16] [17] , other factors than CXCR4-mediated tracer accumulation seem to be responsible for the persistent retention of hepatic 177 Lu-activity in humans.
Overall, absorbed liver doses calculated from mouse biodistribution data and from patient dosimetry in this study, both pre-therapeutically and during [ 177 Lu]pentixather PRRT, were highly consistent and also in agreement with patient data obtained in the aforementioned parallel patient studies, where liver doses ranging from 0.37 mGy/MBq to 0.85 mGy/MBq were observed [38, 39] . However, due to the substantially lower renal activity retention in mice (Figure 3B ), the mouse data failed to accurately predict the human kidney dose, which ranged from 0.48 to 3.07 mGy/MBq in the pre-therapeutic dosimetry assessments (2.51 mGy/MBq in the present patient), but was reduced by app. 40% by nephroprotective treatment during therapy [38, 39] .
As mentioned, the primary goal of this study was the comprehensive characterization of [ 177 [51] . The tolerance of the pentixather scaffold towards complexation with different radiometals (Table 1) , ranging from high-energy beta-emitters ( 90 Y) to alpha-emitters ( 213 Bi), without biasing CXCR4 affinity provides the option to specifically select the best-suited radionuclide for targeting tumors of a given size, from larger tumor masses down to micrometastases. Recent insights into the regulation of CXCR4 expression and function by specific chemotherapeutics may also contribute to improving the efficacy of CXCR4-directed endoradiotherapy using the pentixather platform. For example, pronounced CXCR4 upregulation was observed by daunomycin treatment of selected AML cell lines [52] , leading to more effective chemosensitization of these cells by CXCR4-targeted treatment with AMD3100. This effect may also help to improve uptake of CXCR4-targeted therapeutic vectors such as radiometal-labeled pentixather and thus promote the efficacy of endoradiotherapeutic treatment.
In summary, the detailed preclinical characterization of [ 177 Lu]pentixather demonstrates its excellent CXCR4 targeting characteristics, both in vitro and in vivo, along with a suitable pharmacokinetic profile for efficient tracer delivery to the target tissues as well as favorable overall dosimetry. Ongoing evaluation of [ 177 Lu]pentixather, both preclinically in patient-derived lymphoma and leukemia xenograft models and clinically in patients with hematological cancers will help to further assess its potential role in the endoradiotherapeutic treatment of CXCR4-overexpressing malignancies.
